Armata Pharmaceuticals Inc (DE:TG1N)
STUTTGART:TG1N
TG1N Stock Chart & Stats
€9.15
-€0.01(-0.52%)
At close: 4:00 PM EST
€9.15
-€0.01(-0.52%)
Day’s Range― - ―
52-Week Range€0.70 - €10.30
Previous CloseN/A
Volume0.00
Average Volume (3M)189.00
Market Cap
€347.35M
Enterprise Value€686.69M
Total Cash (Recent Filing)€8.69M
Total Debt (Recent Filing)€288.02M
Price to Earnings (P/E)―
Beta1.81
Next Earnings
May 07, 2026EPS Estimate
-0.32Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.92
Shares Outstanding36,632,774
10 Day Avg. Volume50
30 Day Avg. Volume189
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)-1.04
Price to Sales (P/S)46.41
P/FCF Ratio-8.65
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€15.00Price Target Upside63.98% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.94
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Clinical EfficacyPhase 2a diSArm results showed AP-SA02 added to standard antibiotics produced substantially better clinical response with no evidence of relapse in the AP-SA02 arm, supporting its potential as a frontline adjunct therapy.
Manufacturing ReadinessA newly commissioned cGMP phage manufacturing facility with successful initial production runs demonstrates operational readiness to support pivotal trials and potential commercial supply.
Regulatory PathwayFDA written feedback and End-of-Phase-2 agreement support advancing AP-SA02 into a superiority-based Phase 3, reducing regulatory uncertainty and strengthening the path toward a marketing application.
Bears Say
Execution RiskInitiation of the pivotal trial depends on completing regulatory, manufacturing, and operational milestones, so delays or unmet requirements in any area could postpone trial start and development progress.
Financial PositionLimited cash combined with a substantial debt load creates financing pressure that may necessitate additional funding and lead to shareholder dilution.
Formulary And ReimbursementHospitals will demand clear clinical advantage and demonstrable cost savings for formulary inclusion, so failure to show economic benefit could constrain commercial uptake.
Armata Pharmaceuticals News
TG1N FAQ
What was Armata Pharmaceuticals Inc’s price range in the past 12 months?
Armata Pharmaceuticals Inc lowest stock price was €0.70 and its highest was €10.30 in the past 12 months.
What is Armata Pharmaceuticals Inc’s market cap?
Armata Pharmaceuticals Inc’s market cap is €347.35M.
When is Armata Pharmaceuticals Inc’s upcoming earnings report date?
Armata Pharmaceuticals Inc’s upcoming earnings report date is May 07, 2026 which is in 26 days.
How were Armata Pharmaceuticals Inc’s earnings last quarter?
Armata Pharmaceuticals Inc released its earnings results on Mar 25, 2026. The company reported -€2.916 earnings per share for the quarter, missing the consensus estimate of -€0.239 by -€2.677.
Is Armata Pharmaceuticals Inc overvalued?
According to Wall Street analysts Armata Pharmaceuticals Inc’s price is currently Undervalued.
Does Armata Pharmaceuticals Inc pay dividends?
Armata Pharmaceuticals Inc does not currently pay dividends.
What is Armata Pharmaceuticals Inc’s EPS estimate?
Armata Pharmaceuticals Inc’s EPS estimate is -0.32.
How many shares outstanding does Armata Pharmaceuticals Inc have?
Armata Pharmaceuticals Inc has 36,632,774 shares outstanding.
What happened to Armata Pharmaceuticals Inc’s price movement after its last earnings report?
Armata Pharmaceuticals Inc reported an EPS of -€2.916 in its last earnings report, missing expectations of -€0.239. Following the earnings report the stock price went up 11.486%.
Which hedge fund is a major shareholder of Armata Pharmaceuticals Inc?
Currently, no hedge funds are holding shares in DE:TG1N
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Armata Pharmaceuticals Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
€15.00 (63.98% Upside)
€15.00 (63.98% Upside)
Blogger Sentiment
Bearish
DE:TG1N Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
134.55%
12-Months-Change
Fundamentals
Return on Equity
158.91%
Trailing 12-Months
Asset Growth
-13.23%
Trailing 12-Months
Company Description
Armata Pharmaceuticals Inc
Armata Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on the development of targeted bacteriophage therapeutics for antibiotic-resistant infections worldwide. It develops its products using its proprietary bacteriophage-based technology. The company's product candidates include AP-SA02 for the treatment of Staphylococcus aureus bacteremia; AP-PA02 for Pseudomonas aeruginosa; and AP-PA03 for the treatment of pneumonia. It has a partnership agreement with Merck & Co. for developing synthetic bacteriophage candidates to target undisclosed infectious disease agents. The company is headquartered in Marina del Rey, California.
TG1N Stock 12 Month Forecast
Average Price Target
€15.00
▲(63.98% Upside)
Technical Analysis
Options Prices
Currently, No data available
---